Skip to main content
ENDO 2026 Main banner

Adipose Tissue_Appetite_and Obesity

MON-727 - Participant-Reported Weight Reduction and Reasons for Continuing or Discontinuing Tirzepatide Treatment: Insights from the PERCEPTIONS Longitudinal Survey at 3 Months

Monday, June 15, 2026
9:00 AM - 2:00 PM CT
Disclosure(s):
Theresa Hunter Gibble, PhD, MPH, MS: No relevant disclosure to display


Objective:
This study aimed to understand the reasons for continuing or discontinuing tirzepatide treatment in employed adults with obesity or overweight. Change in body weight was also assessed among those remaining on tirzepatide treatment at 3 months.

Methods:
We assessed 3-month follow-up data from the PERCEPTIONS survey collected from June 2025–February 2026 in the United States. This ongoing electronic longitudinal survey collects data to evaluate experiences with tirzepatide treatment including weight change, reasons for continuation/discontinuation, insurance and workplace experiences, and changes in health-related quality of life. At baseline, participants were full-time employees without type 2 diabetes who were obesity medication–eligible (body mass index [BMI] ≥30 kg/m2, or 27-29.9 kg/m2 with ≥1 obesity-related complication) and had initiated tirzepatide treatment. Participants reported reasons for continuing or discontinuing tirzepatide treatment and self-reported height and weight, which were used to calculate BMI and change in body weight from baseline.

Results:
A total of 468 adults (mean [standard deviation (SD)] age 46.0 [11.6] years, 76.9% female, 69.2% White, mean [SD] BMI 38.4 [8.4] kg/m2) initiated tirzepatide and completed both the baseline and 3-month assessments. Most participants (79.3%) were glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve at baseline; the remaining 20.7% had taken at least one other GLP-1 RA. After 3 months, 98.5% (n=461) of participants were still taking tirzepatide while 1.5% (n=7) had discontinued treatment. The top 5 reasons reported for continuing tirzepatide treatment were having experienced weight loss (76.1%), desire to improve health and wellbeing (65.5%), not having achieved goal weight (38.6%), health care clinician recommendation (28.2%), and having experienced improvement in physical functioning (23.0%). The top 2 reasons for discontinuing tirzepatide treatment were inability to afford the monthly cost (57.1%; n=4) and health insurance no longer covering tirzepatide (42.9%; n=3). For those remaining on tirzepatide treatment with weight data available, the mean (SD) change in body weight at 3 months was –13.8 (11.6) pounds among GLP-1 RA–naïve participants (n=359) and –10.2 (12.1) pounds among GLP-1 RA–experienced participants (n=91).

Conclusion:
Most participants who initiated tirzepatide remained on treatment at 3 months. The main drivers for continuing treatment were weight loss and wanting to improve health and wellbeing, and the main reason for discontinuing treatment was affordability.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*